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Abstract
In recent years we have gained great insight
into the molecular pathogenesis of the 5q- syn-
drome,  a  distinct  subtype  of  myelodysplasia.
The demonstration of haploinsufficiency of the
ribosomal gene RPS14 (mapping to the com-
monly deleted region) and the finding that this
is the cause of the erythroid defect in the 5q-
syndrome represent major advances. A mouse
model of the human 5q- syndrome generated
by large-scale deletion of the Cd74-Nid67 in-
terval (containing RPS14) further supports a
critical role for RPS14 haploinsufficiency. It is
widely accepted that ribosomal deficiency re-
sults in p53 activation and defective erythro-
poiesis and the crossing of the ‘5q- mice’ with
p53 deficient mice ameliorated the erythroid
progenitor defect. Emerging data suggests that
the  p53  activation  observed  in  the  mouse
model may also apply to the human 5q- syn-
drome.
The 5q- syndrome
The 5q- syndrome was first described in
1974 by Van den Berghe who reported the
consistent association of the deletion of the
long arm of chromosome 5 [del(5q)] with
the  following  hematological  features:
macrocytosis,  anemia,  normal  or  high
platelet count and hypolobulated megakary-
ocytes in the bone marrow.1 From the ear-
liest studies a good prognosis and a marked
female  preponderance  have  also  been  re-
ported.2,3 The 5q- syndrome is widely consid-
ered the most distinct of all the myelodys-
plastic  syndromes  and,  importantly,  this
MDS  subtype  is  characterized  by  a  clear
genotype-phenotype  relationship  which  is
not  observed  in  other  MDS  and  acute
myeloid  leukemia  (AML)  characterized  by
chromosomal deletions. The 5q- syndrome is
now recognized as a distinct clinical entity
according to the WHO classification and is
defined by a medullary blast count of <5%
and the presence of the del(5q) as the sole
karyotypic abnormality.4
Mapping the commonly deleted
region and identifying candidate
genes
The identification of significant genes asso-
ciated with chromosome deletions in human
leukaemia  has  proven  challenging.  The
del(5q) in the 5q- syndrome is considered to
mark  the  location  for  a  gene(s)  the  loss  of
which may affect important processes such as
growth  control  and  normal  hematopoiesis.2
The basis for research on deletions such as the
del(5q) in the 5q- syndrome is well known. The
first step is to characterize the deletions and to
identify the commonly deleted region (CDR)
i.e. the region of deletion shared by all patients
as this localises the gene(s) for further study.
Our group in Oxford identified the CDR of the
5q- syndrome5,6 and have since narrowed the
CDR to the approximately 1.5 Mb interval at
5q32 flanked by D5S413 and the GLRA1 gene.7
We  subsequently  generated  a  transcription
map of the CDR and noted several promising
candidate genes map within this region, in-
cluding the tumour suppressor gene SPARC,
and RPS14, a component of the 40S ribosomal
subunit.7,8 The next step in our research was
the sequencing of all the 40 genes that map
within the CDR in a group of patients with the
5q- syndrome.8 The gene sequencing is critical
to understanding the pathogenesis of the 5q-
syndrome; if Knudsen’s two hit model9 applied
to this disorder there would be loss of one al-
lele of a gene and a mutation of the remaining
copy of the same gene. We have sequenced all
the genes in the CDR and no mutations have
been identified.8 This is a key step in deter-
mining  the  molecular  basis  of  the  5q-  syn-
drome since it brings forward the considera-
tion of haploinsufficiency (a gene dosage ef-
fect resulting from the loss of one allele of a
gene)10 as  the  basis  of  the  5q-  syndrome.
There has been growing recognition of hap-
loinsufficiency as a cancer model over the last
decade and we believe that this is the correct
model for the 5q- syndrome.
Haploinsufficiency of RPS14 causes
the erythroid defect 
in the 5q- syndrome
We have recently demonstrated haploinsuf-
ficiency of the ribosomal gene RPS14 in the
CD34+  cells  of  patients  with  the  5q-  syn-
drome.8 The genes in the 5q- syndrome CDR
were studied by an RNA-mediated interference
(RNAi)- based approach by Ebert et al. and it
was  shown  that  partial  loss  of  function
(hapolinsufficiency)  of  RPS14  in  normal
hematopoietic stem cells resulted in a block in
erythroid differentiation with relative preser-
vation  of  megakaryocyte  differentiation11
closely mirroring the defects observed in the
5q- syndrome. Moreover, forced expression of
an RPS14 cDNA in primary bone marrow cells
from patients with the 5q- syndrome rescued
the phenotype, strongly suggesting that RPS14
is a 5q- syndrome gene.11
That reduced expression of a ribosomal pro-
tein plays a key role in the development of a
myeloid  malignancy  may  initially  seem  sur-
prising. However, Diamond-Blackfan anaemia
(DBA),  a  congenital  hypoplastic  anemia,  is
also caused by haploinsufficiency of certain ri-
bosomal proteins. The phenotype of DBA is re-
markably similar to the 5q- syndrome since pa-
tients have a severe anaemia, macrocytosis,
relative preservation of the platelet and neu-
trophil  counts,  erythroid  hypoplasia  in  the
bone  marrow  and  an  increased  risk  of
leukaemia.12 Mutations in RPS19, required for
the maturation of 40S ribosomal subunits, are
found in approximately 25% of DBA patients
and  lead  to  haploinsufficiency  of  RPS19.13,14
Deficiency of RPS19 has been shown to block
proliferation of immature erythroid progenitor
cells.15 Interestingly DBA has been associated
with mutations now in a number of different
ribosomal  protein  genes  including  RPS19,
RPS24,  RPS17,  RPL35A,  RPL5,  RPL11,  and
RPS7 in approximately 43% of patients.16 Im-
portantly,  an  acquired  internal  deletion  on
chromosome 5q involving the CDR of the 5q-
syndrome (and loss of RPS14) has been re-
cently described in a patient with non-classical
DBA.17
The anaemia in DBA and the 5q- syndrome
is due to a failure of erythropoiesis and in-
triguingly  both  disorders  show  haploinsuffi-
ciency  for  ribosomal  proteins,  RPS19  and
RPS14 respectively, required for the matura-
tion of 40S ribosomal subunits.13,18 Mutations
in RPS19 impair pre-rRNA processing of the
18S rRNA, which leads to decreased production
of the 40S ribosomal subunit19 and RPS14 hap-
loinsufficiency causes a similar outcome,11thus
linking the pathogenesis of the 5q- syndrome to
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DBA.  Moreover,  similarities  in  the  defective
gene  expression  patterns  observed  in  the
CD34+ cells of patients with DBA and patients
with the 5q- syndrome were recently reported by
Pellagatti et al., including the down-regulation
of multiple ribosomal genes and genes involved
in translation initiation and the up-regulation
of  several  proapoptotic  genes,  further  sug-
gesting that the 5q- syndrome represents a dis-
order of aberrant ribosome biogenesis.20 These
abnormalities may lead to impairment of ribo-
some biogenesis and subsequent reduction of
protein translation capacity, a defect which may
be of particular importance for developing ery-
throid cells, whose survival and division require
large amounts of protein synthesis.
A number of other bone marrow failure syn-
dromes are caused by defects in genes known
to play a role in ribosome biogensis including
Shwachman-Diamond  Syndrome,21 Dysker-
atosis  Congenita,  Cartilage  Hair  Hypoplasia,
and the demonstration of RPS14 as a 5q- syn-
drome gene further suggests that defective ri-
bosomal biogenesis may have a more general
relevance in leukaemogenesis.22
P53 activation underlies 
the anemia in the 5q- syndrome
P53, a key regulator of cell growth and cell
death,  is  maintained  at  a  low  level  during
normal cell growth and is activated in response
to  various  cellular  stresses.  Impaired  ribo-
somal biogenesis, such as that resulting from
haploinsufficiency  of  certain  ribosomal  pro-
teins  can  cause  nucleolar  stress.23,24 Signal
mediator  proteins  then  activate  p53  by  in-
hibiting  ubiquitylation  (and  degradation)  by
MDM2, the major regulator of p53.25 Activated
p53  then  promotes  the  transcription  of  its
many target genes resulting in p53-dependent
cell cycle arrest or apoptosis. It is now widely
recognised that p53 activation is a common re-
sponse to deficiency of ribosomal proteins in
various diseases including DBA and Treacher
Collins syndrome.24,26
We have recently generated a mouse model
of the 5q- syndrome using large-scale chromo-
somal engineering.27 Haploinsufficiency of the
Cd74-Nid67 interval caused macrocytic anemia,
prominent erythroid dysplasia and monolobu-
lated megakaryocytes in the bone marrow. The
Cd74-Nid67 interval on mouse chromosome 18
is syntenic with a region within the CDR of the
human 5q- syndrome7 and contains 8 known
genes of which 2 have been excluded (Ndst1
and Cd74) leaving Rps14, Synpo, Myoz3, Dctn-4,
Rbm22 and Nid67 as candidates.27 It is most
probable that RPS14 is the major gene in rela-
tion to the phenotype. The ‘5q- mouse’ has a de-
fective  bone  marrow  progenitor  development
and  bone  marrow  cells  expressing  high
amounts of p53 with increased apoptosis. The
5q- mouse was crossed with p53 deficient mice
and  significantly  this  rescued  the  progenitor
cell  defect,  restoring  hematopoietic  stem  cell
bone marrow populations.27 These data suggest
that a p53-dependent mechanism underlies the
pathophysiology of the 5q- syndrome.
We have recently shown that induction of
p53 and up-regulation of the p53 pathway oc-
curs in the human 5q- syndrome28 and Dutt et
al. have demonstrated that haploinsufficiency
of RPS14 indeed causes activation of p53 in
human erythroid cells.29
Cooperating events in the 
development  of the 5q- syndrome
There  is  compelling  data  suggesting  that
haploinsufficency  of  RPS14 gene  causes  the
erythroid differentiation defect of the 5q- syn-
drome11,27 and  there  is  evidence  suggesting
that  loss  of  the  miRNA  genes  miR-145  and
miR-146a (mapping within and adjacent to the
CDR of the 5q- syndrome, respectively) may
play a role in the abnormalities of themegakary-
ocyte lineage observed.30 Thus several cooper-
ating genetic events may be necessary in the
development of the 5q- syndrome.31 Whether
RPS14 or  these  microRNA  genes  are  causal
genes  in  relation  to  producing  a  clonal
haematopoietic disorder, and whether haploin-
sufficiency of an additional gene or genes is
involved are important questions remaining to
be  answered.  Haploinsufficiency  of  other
genes localised within the CDR such as the tu-
mour suppressor gene SPARC, or indeed muta-
tions  in  genes  mapping  elsewhere  in  the
genome, could play a role in establishing clonal
dominance.32 Clearly further mouse knockout
models and whole genome sequencing studies
might prove very informative in relation to all
these questions.
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